|
1
|
Neumann FJ, Sousa-Uva M, Ahlsson A,
Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V,
Head SJ, et al: 2018 ESC/EACTS guidelines on myocardial
revascularization. Eur Heart J. 40:87–165. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Knuuti J, Wijns W, Saraste A, Capodanno D,
Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C,
Cuisset T, et al: 2019 ESC guidelines for the diagnosis and
management of chronic coronary syndromes. Eur Heart J. 41:407–477.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Collet JP, Thiele H, Barbato E, Barthelemy
O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T,
Folliguet T, et al: 2020 ESC guidelines for the management of acute
coronary syndromes in patients presenting without persistent
ST-segment elevation. Eur Heart J ehaa575, 2020.
|
|
4
|
Gruntzig AR, Senning A and Siegenthaler
WE: Nonoperative dilatation of coronary-artery stenosis:
Percutaneous transluminal coronary angioplasty. N Engl J Med.
301:61–68. 1979.PubMed/NCBI View Article : Google Scholar
|
|
5
|
McKavanagh P, Zawadowski G, Ahmed N and
Kutryk M: The evolution of coronary stents. Expert Rev Cardiovasc
Ther. 16:219–228. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Huang KN, Grandi SM, Filion KB and
Eisenberg MJ: Late and very late stent thrombosis in patients with
second-generation drug-eluting stents. Can J Cardiol. 29:1488–1494.
2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chang M and Park DW: Optimal duration of
dual antiplatelet therapy after implantation of drug-eluting
stents: Shorter or longer? Cardiol Ther. 3:1–12. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Hassan AK, Bergheanu SC, Stijnen T, van
der Hoeven BL, Snoep JD, Plevier JW, Schalij MJ and Wouter Jukema
J: Late stent malapposition risk is higher after drug-eluting stent
compared with bare-metal stent implantation and associates with
late stent thrombosis. Eur Heart J. 31:1172–1180. 2010.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Cassese S, Byrne RA, Tada T, Pinieck S,
Joner M, Ibrahim T, King LA, Fusaro M, Laugwitz KL and Kastrati A:
Incidence and predictors of restenosis after coronary stenting in
10 004 patients with surveillance angiography. Heart. 100:153–159.
2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Byrne RA, Joner M and Kastrati A: Stent
thrombosis and restenosis: What have we learned and where are we
going? The andreas gruntzig lecture ESC 2014. Eur Heart J.
36:3320–3331. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Madhavan MV, Kirtane AJ, Redfors B,
Genereux P, Ben-Yehuda O, Palmerini T, Benedetto U, Biondi-Zoccai
G, Smits PC, von Birgelen C, et al: Stent-related adverse events
>1 year after percutaneous coronary intervention. J Am Coll
Cardiol. 75:590–604. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Loh JP, Pendyala LK, Kitabata H, Torguson
R, Omar A, Minha S, Chen F, Satler LF, Pichard AD and Waksman R:
Comparison of outcomes after percutaneous coronary intervention
among different coronary subsets (stable and unstable angina
pectoris and ST-segment and non-ST-segment myocardial infarction).
Am J Cardiol. 113:1794–1801. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Gonzalo N, Barlis P, Serruys PW,
Garcia-Garcia HM, Onuma Y, Ligthart J and Regar E: Incomplete stent
apposition and delayed tissue coverage are more frequent in
drug-eluting stents implanted during primary percutaneous coronary
intervention for ST-segment elevation myocardial infarction than in
drug-eluting stents implanted for stable/unstable angina: Insights
from optical coherence tomography. JACC Cardiovasc Interv.
2:445–452. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hung MJ, Hsu KH, Chang NC, Tsimikas S and
Hung MY: Prevalence of coronary artery spasm after stent placement
and its association with inflammation. Int J Cardiol. 179:252–255.
2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Ang H, Lin J, Huang YY, Chong TT, Cassese
S, Joner M and Foin N: Drug-Coated balloons: Technologies and
clinical applications. Curr Pharm Des. 24:381–396. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Jeger RV, Eccleshall S, Wan Ahmad WA, Ge
J, Poerner TC, Shin ES, Alfonso F, Latib A, Ong PJ, Rissanen TT, et
al: Drug-coated balloons for coronary artery disease: Third report
of the international DCB consensus group. JACC Cardiovasc Interv.
13:1391–1402. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Scheller B, Hehrlein C, Bocksch W, Rutsch
W, Haghi D, Dietz U, Bohm M and Speck U: Treatment of coronary
in-stent restenosis with a paclitaxel-coated balloon catheter. N
Engl J Med. 355:2113–2124. 2006.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Giacoppo D, Alfonso F, Xu B, Claessen
BEPM, Adriaenssens T, Jensen C, Perez-Vizcayno MJ, Kang DY,
Degenhardt R, Pleva L, et al: Paclitaxel-coated balloon angioplasty
vs. drug-eluting stenting for the treatment of coronary in-stent
restenosis: A comprehensive, collaborative, individual patient data
meta-analysis of 10 randomized clinical trials (DAEDALUS study).
Eur Heart J. 41:3715–3728. 2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Rittger H, Brachmann J, Sinha AM,
Waliszewski M, Ohlow M, Brugger A, Thiele H, Birkemeyer R, Kurowski
V, Breithardt OA, et al: A randomized, multicenter, single-blinded
trial comparing paclitaxel-coated balloon angioplasty with plain
balloon angioplasty in drug-eluting stent restenosis: The
PEPCAD-DES study. J Am Coll Cardiol. 59:1377–1382. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Scheller B, Clever YP, Kelsch B, Hehrlein
C, Bocksch W, Rutsch W, Haghi D, Dietz U, Speck U, Böhm M and
Cremers B: Long-term follow-up after treatment of coronary in-stent
restenosis with a paclitaxel-coated balloon catheter. JACC
Cardiovasc Interv. 5:323–330. 2012.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Jeger RV, Farah A, Ohlow MA, Mangner N,
Mobius-Winkler S, Leibundgut G, Weilenmann D, Wohrle J, Richter S,
Schreiber M, et al: Drug-coated balloons for small coronary artery
disease (BASKET-SMALL 2): An open-label randomised non-inferiority
trial. Lancet. 392:849–856. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cortese B, Micheli A, Picchi A, Coppolaro
A, Bandinelli L, Severi S and Limbruno U: Paclitaxel-coated balloon
versus drug-eluting stent during PCI of small coronary vessels, a
prospective randomised clinical trial. The PICCOLETO study. Heart.
96:1291–1296. 2010.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Latib A, Colombo A, Castriota F, Micari A,
Cremonesi A, De Felice F, Marchese A, Tespili M, Presbitero P,
Sgueglia GA, et al: A randomized multicenter study comparing a
paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in
small coronary vessels: The BELLO (Balloon elution and late loss
optimization) study. J Am Coll Cardiol. 60:2473–2480.
2012.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Waksman R and Pakala R: Drug-eluting
balloon: The comeback kid? Circ Cardiovasc Interv. 2:352–358.
2009.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wessely R: New drug-eluting stent
concepts. Nat Rev Cardiol. 7:194–203. 2010.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Axel DI, Kunert W, Goggelmann C, Oberhoff
M, Herdeg C, Kuttner A, Wild DH, Brehm BR, Riessen R, Köveker G and
Karsch KR: Paclitaxel inhibits arterial smooth muscle cell
proliferation and migration in vitro and in vivo using local drug
delivery. Circulation. 96:636–645. 1997.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yerasi C, Case BC, Forrestal BJ, Torguson
R, Weintraub WS, Garcia-Garcia HM and Waksman R: Drug-coated
balloon for de novo coronary artery disease: JACC state-of-the-art
review. J Am Coll Cardiol. 75:1061–1073. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Cheng Y, Leon MB and Granada JF: An update
on the clinical use of drug-coated balloons in percutaneous
coronary interventions. Expert Opin Drug Deliv. 13:859–872.
2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Verheye S, Vrolix M, Kumsars I, Erglis A,
Sondore D, Agostoni P, Cornelis K, Janssens L, Maeng M, Slagboom T,
et al: The SABRE trial (Sirolimus angioplasty balloon for coronary
in-stent restenosis): Angiographic results and 1-year clinical
outcomes. JACC Cardiovasc Interv. 10:2029–2037. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ali RM, Abdul Kader MASK, Wan Ahmad WA,
Ong TK, Liew HB, Omar AF, Mahmood Zuhdi AS, Nuruddin AA, Schnorr B
and Scheller B: Treatment of coronary drug-eluting stent restenosis
by a sirolimus- or paclitaxel-coated balloon. JACC Cardiovasc
Interv. 12:558–566. 2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Cortese B, Di Palma G and Latini R: Magic
Touch(R): Preliminary clinical evidence with a novel
sirolimus drug coated balloon. Minerva Cardioangiol. 66:508–517.
2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Scheller B, Speck U, Abramjuk C, Bernhardt
U, Bohm M and Nickenig G: Paclitaxel balloon coating, a novel
method for prevention and therapy of restenosis. Circulation.
110:810–814. 2004.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ibanez B, James S, Agewall S, Antunes MJ,
Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA,
Halvorsen S, et al: 2017 ESC Guidelines for the management of acute
myocardial infarction in patients presenting with ST-segment
elevation: The Task Force for the management of acute myocardial
infarction in patients presenting with ST-segment elevation of the
European society of cardiology (ESC). Eur Heart J. 39:119–177.
2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Alawami M, Sadler M, Kasargod C, Watson T,
Webster M and Ruygrok P: Outcomes of patients with ST elevation
myocardial infarction in the era of second-generation drug eluting
stents; five-year follow-up. N Z Med J. 132:34–41. 2019.PubMed/NCBI
|
|
35
|
Herdeg C, Oberhoff M, Baumbach A, Blattner
A, Axel DI, Schroder S, Heinle H and Karsch KR: Local paclitaxel
delivery for the prevention of restenosis: Biological effects and
efficacy in vivo. J Am Coll Cardiol. 35:1969–1976. 2000.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Oberhoff M, Kunert W, Herdeg C, Kuttner A,
Kranzhofer A, Horch B, Baumbach A and Karsch KR: Inhibition of
smooth muscle cell proliferation after local drug delivery of the
antimitotic drug paclitaxel using a porous balloon catheter. Basic
Res Cardiol. 96:275–282. 2001.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Ho HH, Tan J, Ooi YW, Loh KK, Aung TH, Yin
NT, Sinaga DA, Jafary FH and Ong PJ: Preliminary experience with
drug-coated balloon angioplasty in primary percutaneous coronary
intervention. World J Cardiol. 7:311–314. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Vos NS, Dirksen MT, Vink MA, van Nooijen
FC, Amoroso G, Herrman JP, Kiemeneij F, Patterson MS, Slagboom T
and van der Schaaf RJ: Safety and feasibility of a
PAclitaxel-eluting balloon angioplasty in Primary Percutaneous
coronary intervention in Amsterdam (PAPPA): One-year clinical
outcome of a pilot study. EuroIntervention. 10:584–590.
2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Gobic D, Tomulic V, Lulic D, Zidan D,
Brusich S, Jakljevic T and Zaputovic L: Drug-coated balloon versus
drug-eluting stent in primary percutaneous coronary intervention: A
feasibility study. Am J Med Sci. 354:553–560. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Belkacemi A, Agostoni P, Nathoe HM,
Voskuil M, Shao C, Van Belle E, Wildbergh T, Politi L, Doevendans
PA, Sangiorgi GM and Stella PR: First results of the DEB-AMI (drug
eluting balloon in acute ST-segment elevation myocardial
infarction) trial: A multicenter randomized comparison of
drug-eluting balloon plus bare-metal stent versus bare-metal stent
versus drug-eluting stent in primary percutaneous coronary
intervention with 6-month angiographic, intravascular, functional,
and clinical outcomes. J Am Coll Cardiol. 59:2327–2337.
2012.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Nijhoff F, Agostoni P, Belkacemi A, Nathoe
HM, Voskuil M, Samim M, Doevendans PA and Stella PR: Primary
percutaneous coronary intervention by drug-eluting balloon
angioplasty: The nonrandomized fourth arm of the DEB-AMI
(drug-eluting balloon in ST-segment elevation myocardial
infarction) trial. Catheter Cardiovasc Interv. 86 (Suppl
1):S34–S44. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Vos NS, Fagel ND, Amoroso G, Herrman JR,
Patterson MS, Piers LH, van der Schaaf RJ, Slagboom T and Vink MA:
Paclitaxel-coated balloon angioplasty versus drug-eluting stent in
acute myocardial infarction: The REVELATION randomized trial. JACC
Cardiovasc Interv. 12:1691–1699. 2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Scheller B, Ohlow MA, Ewen S, Kische S,
Rudolph TK, Clever YP, Wagner A, Richter S, El-Garhy M, Böhm M, et
al: Bare metal or drug-eluting stent versus drug-coated balloon in
non-ST-elevation myocardial infarction: The randomised PEPCAD
NSTEMI trial. EuroIntervention. 15:1527–1533. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Liu Y, Zhang YJ, Deng LX, Yin ZY, Hu T,
Wang Q, Li Y, Li JY, Guo WY, Mou FJ and Tao L: 12-Month clinical
results of drug-coated balloons for de novo coronary lesion in
vessels exceeding 3.0 mm. Int J Cardiovasc Imaging. 35:579–586.
2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Venetsanos D, Lawesson SS, Panayi G, Todt
T, Berglund U, Swahn E and Alfredsson J: Long-term efficacy of drug
coated balloons compared with new generation drug-eluting stents
for the treatment of de novo coronary artery lesions. Catheter
Cardiovasc Interv. 92:E317–E326. 2018.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Megaly M, Buda KG, Xenogiannis I, Vemmou
E, Nikolakopoulos I, Saad M, Rinfret S, Abbott JD, Aronow HD,
Garcia S, et al: Systematic review and meta-analysis of short-term
outcomes with drug-coated balloons vs. stenting in acute myocardial
infarction. Cardiovasc Interv Ther: Oct 10, 2020 (Epub ahead of
print).
|
|
47
|
Claessen BE, Henriques JP and Dangas GD:
Clinical studies with sirolimus, zotarolimus, everolimus, and
biolimus A9 drug-eluting stent systems. Curr Pharm Des.
16:4012–4024. 2010.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Navarese EP, Tandjung K, Claessen B,
Andreotti F, Kowalewski M, Kandzari DE, Kereiakes DJ, Waksman R,
Mauri L, Meredith IT, et al: Safety and efficacy outcomes of first
and second generation durable polymer drug eluting stents and
biodegradable polymer biolimus eluting stents in clinical practice:
Comprehensive network meta-analysis. BMJ. 347(f6530)2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Sabate M, Raber L, Heg D, Brugaletta S,
Kelbaek H, Cequier A, Ostojic M, Iniguez A, Tuller D, Serra A, et
al: Comparison of newer-generation drug-eluting with bare-metal
stents in patients with acute ST-segment elevation myocardial
infarction: A pooled analysis of the EXAMINATION (clinical
Evaluation of the Xience-V stent in Acute Myocardial INfArcTION)
and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible
Stent Coating With Bare Metal Stents in Acute ST-Elevation
Myocardial Infarction) trials. JACC Cardiovasc Interv. 7:55–63.
2014.PubMed/NCBI View Article : Google Scholar
|
